Evidence map›Paper›PMID 41179199›Full record

ArticleACS omega2025

Light-Induced Degradation of Tamoxifen in Liquid Formulations: Multivariate Kinetic Profiling, Stabilization Strategies, and Estrogen Receptor Binding.

Maria Antonietta Occhiuzzi, Martina Chieffallo, Giuseppina Ioele, Giancarlo Di Pinto, Giuseppe Cirillo, Michele De Luca, Antonio Garofalo, Fedora Grande

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria Antonietta OcchiuzziDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende 87036, Italy.
Martina ChieffalloDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende 87036, Italy.
Giuseppina IoeleDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende 87036, Italy.
Giancarlo Di PintoMedical Oncology Unit, Ferrari Hospital, Castrovillari 87012, Italy.
Giuseppe CirilloDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende 87036, Italy.ORCID https://orcid.org/0000-0002-9592-1333
Michele De LucaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende 87036, Italy.ORCID https://orcid.org/0000-0001-9036-1595
Antonio GarofaloDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende 87036, Italy.
Fedora GrandeDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende 87036, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tamoxifen is the most prescribed drug for the treatment of breast cancer in premenopausal women and prevention of tumor recurrence. The anticancer effect is attributed to its ability to modulate estrogen receptor activity, with the drug's metabolites being more effective than the parent compound. Tamoxifen is sensitive to environmental conditions, leading to the formation of degradation products that may, however, retain biological activity. Herein, the photodegradation of tamoxifen in oral formulations was studied by combining spectrophotometric methodologies and multivariate analysis. The four photoproducts identified have been studied. Stabilization strategies were explored, evaluating both protective packaging precautions and the addition of chemical stabilizers, such as ascorbic acid and quercetin. Molecular docking simulations revealed that all four photoderivatives are capable of binding to the estrogen receptor, suggesting that these compounds may retain, or contribute to, the drug's antitumor activity. These findings not only underscore the importance of formulation and storage conditions in preserving tamoxifen stability and therapeutic efficacy but also provide the first integrated multivariate kinetic and molecular docking analysis of its photodegradation in liquid formulations, offering novel insights into both stability and residual pharmacological activity.

Identifiers

PMID41179199
PMCPMC12572979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.